[Treatment outcomes of parenterally administered dengzhan xixin for treatment of cerebral infaction based on real world hospital injection system data].
Cerebral infarction is one of the indications for parenterally administered Dengzhan Xixin. This study aims to analyze treatment outcomes in patients with cerebral infarction of parenterally administered Dengzhan Xixin, in the real world. Data from 20 national hospitals' hospital injection system (HIS) databases were collected. 1 008 cases of parenterally administered Dengzhan Xixin for the treatment of cerebral infarction were compared with 1 504 cases who did not receive Dengzhan Xixin who acted as the control group. Outcome was defined by mortality or survival following cerebral infarction. It was found that, before controlling for confounding factors, parenterally administered Dengzhan Xixin did not have a significant effect on mortality, P = 0.098 3. Stratified analysis taking into account, age, gender, condition on admission,dosage, and length of treatment found that parenterally administered Dengzhan Xixin had significant effects on cerebral infarction mortality when dosage and length of treatment course were stratification factors; P values were 0.029 3 and 0.030 9 respectively. When applying classic logistic regression to the analysis there was no difference between the observation group and control group, P = 0.106. Generalized boosted models (GBM) and propensity score (PS) weighted Logistic regression, was then applied to balance 72 variables such as age and gender, this found that there were significant differences between the observation and control groups, P < 0.001. This study concludes that parenterally administered Dengzhan Xixin can reduce the mortality of cerebral infarction patients based on existing data. However,there are many known and unknown confounders in retrospectively analysis, and the propensity score can only control for known confounding factors. Therefore, these findings should be considered as a reference for treating cerebral infarction.
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China. ywonline@163.com
Wei
W
Yang
School of Statistics, Renmin University of China, Beijing 100872, China.
Lin
L
Li
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Yan-Ming
YM
Xie
The PLA Navy General Hospital, Beijing 100048, China.
Yan
Y
Zhuang
Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing 100700, China.
Wei
W
Yang
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002544:Cerebral Infarction / Q000188:drug therapy* / Q000401:mortality; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage*; D005260:Female; D006751:Hospital Information Systems / Q000706:statistics & numerical data*; D006801:Humans; D007263:Infusions, Parenteral; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D017063:Outcome Assessment, Health Care; D064792:Pragmatic Clinical Trials as Topic; D057216:Propensity Score; D016896:Treatment Outcome; D055815:Young Adult
D004365:Drugs, Chinese Herbal